Littérature scientifique sur le sujet « Drug-sparing regimen »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Drug-sparing regimen ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Drug-sparing regimen"
Rosa, Rossana, Jose F. Suarez, Marco A. Lorio, Michele I. Morris, Lilian M. Abbo, Jacques Simkins, Giselle Guerra et al. « Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients : Review of 58 cases ». F1000Research 5 (21 décembre 2016) : 2893. http://dx.doi.org/10.12688/f1000research.10414.1.
Texte intégralDutta, Noton K., Abdullah Alsultan, Thomas J. Gniadek, Deborah A. Belchis, Michael L. Pinn, Khisimuzi E. Mdluli, Eric L. Nuermberger, Charles A. Peloquin et Petros C. Karakousis. « Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen ». Antimicrobial Agents and Chemotherapy 57, no 8 (3 juin 2013) : 3910–16. http://dx.doi.org/10.1128/aac.00761-13.
Texte intégralRuzicka, Daniel J., Mayuko Kamakura, Naho Kuroishi, Nobuyuki Oshima, Miyuki Yamatani, Jingbo Yi, Bruce Crawford, Kunihisa Tsukada et Shinichi Oka. « Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting : A large-scale medical claim database analysis in Japan ». PLOS ONE 17, no 6 (14 juin 2022) : e0269779. http://dx.doi.org/10.1371/journal.pone.0269779.
Texte intégralMaggiolo, Franco, Nicola Gianotti, Laura Comi, Elisa Di Filippo, Laura Fumagalli, Silvia Nozza, Laura Galli, Daniela Valenti, Marco Rizzi et Antonella Castagna. « Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects : Final results of the PROBE 2 trial ». Antiviral Therapy 26, no 3-5 (mai 2021) : 51–57. http://dx.doi.org/10.1177/13596535211042226.
Texte intégralSleeper, Rebecca B. « Antipsychotic Dose-Sparing Effect with Addition of Memantine ». Annals of Pharmacotherapy 39, no 9 (septembre 2005) : 1573–76. http://dx.doi.org/10.1345/aph.1g207.
Texte intégralTiberi, Simon, Marie-Christine Payen, Giovanni Sotgiu, Lia D'Ambrosio, Valentina Alarcon Guizado, Jan Willem Alffenaar, Marcos Abdo Arbex et al. « Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB ». European Respiratory Journal 47, no 4 (10 mars 2016) : 1235–43. http://dx.doi.org/10.1183/13993003.02146-2015.
Texte intégralFischl, Margaret A., Ann C. Collier, A. Lisa Mukherjee, Judith E. Feinberg, Lisa M. Demeter, Pablo Tebas, Marina Giuliano et al. « Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen ». AIDS 21, no 3 (janvier 2007) : 325–33. http://dx.doi.org/10.1097/qad.0b013e328011ddfa.
Texte intégralKaroney, Mercy Jelagat, Mathew Kirtptonui Koech, Evangeline Wawira Njiru et Willis Dixon Owino Ong’or. « Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya ». PLOS ONE 17, no 9 (15 septembre 2022) : e0273183. http://dx.doi.org/10.1371/journal.pone.0273183.
Texte intégralStürmer, Martin, Schlomo Staszewski et Hans Wilhelm Doerr. « Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV ». Antiviral Therapy 12, no 5 (juillet 2007) : 695–704. http://dx.doi.org/10.1177/135965350701200514.
Texte intégralKovalskaya, Galina N., Dina Y. Zhukova et Ekaterina N. Mikhalevich. « Interaction of Drugs Used for the Treatment of Cardiovascular Diseases ». Acta Biomedica Scientifica 4, no 1 (4 avril 2019) : 36–42. http://dx.doi.org/10.29413/abs.2019-4.1.6.
Texte intégralThèses sur le sujet "Drug-sparing regimen"
Papot, Emmanuelle. « Coût des traitements antirétroviraux : évaluation de l’impact d’interventions au niveau des prescripteurs et des patients : ANRS-GOTA : Gestion Optimale des Traitements Antirétroviraux ». Electronic Thesis or Diss., Université Paris Cité, 2021. http://www.theses.fr/2021UNIP5253.
Texte intégralAbstract in English:Objectives: The main objective of this project was to evaluate the impact of a series of interventions, addressed to prescribers and patients, on the expenditure on antiretroviral therapies (ART) prescribed in the Department of Infectious and Tropical Diseases (SMIT) of the Bichat Hospital, Paris, France. The secondary objectives included the description of the antiretroviral regimens used, their price, the assessment of the knowledge, beliefs and representations regarding the price of ART, and the acceptability of such interventions, among prescribers and people living with HIV (PWH). At inception, an objective was also to monitor the sustainability of the immuno-virological response for PWH who benefited from an ART switch for economic reasons, and the absence of side effects or of an alteration of the healthcare giver-PWH relationship. Background: In 2014, the economic crisis led the French Health Insurance (Social Security) to pay more attention to the expenses generated by medicines free of charge, which included ART. Generic antiretrovirals came onto the French market, and the guidelines included the concept of ART optimisation for PWH in therapeutic success. This adaptation aimed to increase the comfort of ART intake and to decrease long-term side effects. It also tackled cost criteria, thus, introducing new challenges in the doctor-PWH relationship. Problem: With some information and actions on the proper use of ART, is it possible to curb the increase in ART expenditure without a negative impact on the effectiveness and tolerance of the treatment or on the healthcare giver-PWH relationship? Methods: An interventional before-after study, in order to evaluate the expenditure on ART before and after a series of interventions in the SMIT of Bichat, against control, was developed. The budget impact analysis and therapeutic success evaluation were supplemented with a psychosocial evaluation component based on focus groups with the prescribers and PWH of the SMIT of Bichat, and questionnaires administered to these two populations aiming at studying their perceptions around ART and their price, as well as their experience of these interventions. Results: The 2014 budget impact study at the Bichat site estimated the ARV budget at €48,280,200 and highlighted potential antiretroviral combinations that could be switched to cheaper combinations, with equal efficiency and tolerance, and adapted to the medical profile of PWH. Protease inhibitor (PI) regimens changed to drug-sparing regimen or PI-free regimens, moreover with generic antiretrovirals, were the scenarios with the largest impact in terms of budget reduction. Focus groups (organised in 2015) and questionnaires (administered in 2016) helped identify the themes of the interventions. After consultation of a group of PWH followed up at the SMIT, their healthcare givers and PWH associations, two interventions were developed (a shared-decision making guide on the choice of ART and their price, and a website calculating the price of ART). They were implemented in 2018 in the experimental site. Discussion and conclusion: The generalisability of the interventions developed and of the results of the “pre-interventions assessment” stage was discussed at a national and global level. Subsequently, the post-interventions assessment was affected by the COVID-19 pandemic. Directly, through the mobilisation of people in the fight against COVID-19, and indirectly because of the resulting public health crisis and the resilience of populations. This new context makes any comparison or observation obsolete. ANRS-GOTA was a pilot study in one site, its design, tools and interventions, created and implemented, could however be rolled-out for testing on a larger scale
Livres sur le sujet "Drug-sparing regimen"
Harper, Lorraine, et David Jayne. The patient with vasculitis. Sous la direction de Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0160.
Texte intégralJayne, David. Treatment of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132.
Texte intégralChapitres de livres sur le sujet "Drug-sparing regimen"
Pappas, Peter G. « Fungal Infections in Solid Organ Transplant Recipients ». Dans Clinical Mycology, 470–87. Oxford University PressNew York, NY, 2003. http://dx.doi.org/10.1093/oso/9780195148091.003.0031.
Texte intégralJayne, David. « Treatment of ANCA-associated vasculitis ». Dans Oxford Textbook of Rheumatology, 1103–12. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132_update_001.
Texte intégral